-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ICG-136 in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ICG-136 in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ICG-136 in Acute Myelocytic Leukemia (AML, Acute...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TIN-816 in Sepsis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TIN-816 in Sepsis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TIN-816 in Sepsis Drug Details: TIN-816 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ICG-122 in T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ICG-122 in T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ICG-122 in T-Cell Acute Lymphocytic Leukemia...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rucaparib Camsylate in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rucaparib Camsylate in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rucaparib Camsylate in Pancreatic Ductal Adenocarcinoma Drug Details: Rucaparib...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cemiplimab in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cemiplimab in Relapsed Multiple Myeloma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cemiplimab in Relapsed Multiple Myeloma Drug Details: Cemiplimab (Libtayo) is...
-
Product Insights
Military Engineer Svs – Visakhapatnam IN-ICG Jetty – Andhra Pradesh
Equip yourself with the essential tools needed to make informed and profitable decisions with our Military Engineer Svs - Visakhapatnam IN-ICG Jetty - Andhra Pradesh report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep...
-
Company Profile
Intermediate Capital Group Plc – Company Profile
Intermediate Capital Group Plc (ICG) is a specialist asset manager that manages closed end third party funds and proprietary capital. It operates across various asset classes such as corporate, capital market, real asset and secondary investments. The group offers equity and debt capital to mid-market private companies in North America, Europe, and Asia-Pacific. The capital market invests in senior secured loans, high yield bonds and structured credit products. Its real assets provide dent and equity financing for real estate investments...
Add to Basket -
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ICG-122
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry ICG-122 Drug Details Gene therapy is under development for the treatment of CD4 positive...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ICG-124
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry ICG-124 Drug Details Gene therapy is under development for the treatment of relapsed and/or...